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Abstract
The purpose of this study was to verify the standard procedures and minimum level of knowledge of Italian public laboratories involved
in the management of antifungal susceptibility testing (AST). Two nationwide surveys were performed in 1999 and 2004. One hundred and
two Italian hospitals located in 85 provincial capitals (82.5%) participated to these surveys. In 1999, 28 (27.5%) laboratories versus 16
(15.7%) in 2004 stated that they did not perform any susceptibility testing. Some discrepancies observed in the survey confirm that AST is
difficult to be correctly managed, and that it can be performed only in very well-trained centers. The great variability of the results of MIC
determination and clinical interpretation underlines the urgent need to improve knowledge about indications, method choice, and
interpretative criteria for AST both for clinical microbiologists and clinicians.
D 2007 Elsevier Inc. All rights reserved.
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for microbiologists because of the increasing importance of
clinicians’ requests and the lack of standardization in
technology and in interpretative criteria. However, a
reference method for antifungal susceptibility testing
(AST) of yeasts (Blanc et al., 2005) by the means of a
broth dilution technique was approved in 2002 by the
Clinical Laboratory Standard Institute (CLSI), formerly
known as the National Committee for Clinical Laboratory
Standards (NCCLS, 2002), and in 2003 by the European
Committee on Antimicrobial Susceptibility Testing
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E-mail address: farina.claudio@sancarlo.mi.it (C. Farina ).The Medical Mycology Committee of the Association of
Italian Clinical Microbiologists proposed a national survey
to verify the procedures used in the clinical laboratories
of public hospitals in Italy. In 1999 and in 2004,
180 questionnaires were mailed to the directors of micro-
biology laboratories of public hospitals in 103 cities all over
Italy. Only public hospital laboratories in province capitals
were selected as representative of the average mycological
knowledge of both clinicians and microbiologists.
At the end of both studies, the same number of
questionnaires (102/180, 56.7%) were returned from
85/103 (82.5%) province capitals, even if the geographic
location was different between the surveys. In 1999,
28 (27.5%) laboratories versus 16 (15.7%) in 2004 stated
that they did not perform any susceptibility testing (Jones
et al., 2005). On the contrary, 17 (16.7%) in 1999 versus
13 (12.7%) in 2004 confirmed that AST was part of the
routine work. In 57 (55.9%) versus 73 (71.6%) hospitalsfectious Disease 57 (2007) 225–227
Table 1







Blood 74 4 8
CSF 71 7 8
Feces 3 68 15
Urine 3 26 57
Pharyngeal swab 10 54 22
Nasal swab 8 57 21
Sputum 18 42 26
Sterile fluids 32 28 26
Vaginal exudate 11 39 17
Urethral exudate 14 54 18








Etest + Sensititre 5 (6.3%)
ATB Fungus + Sensititre 5 (6.3%)
Fungitest 4 (5.1%)
ATB Plus 1 (1.3%)
ATB Fungus +Etest 1 (1.3%)
Total 79
C. Farina et al. / Diagnostic Microbiology and Infectious Disease 57 (2007) 225–227226(in 1999 and 2004, respectively), AST was performed only
in selected clinical cases.
AST was performed on the basis either of clinician’s
request in 27/57 (47.4%) versus 29/73 (39.7%) or of
microbiologist’s decision in the remaining cases (in 1999
and 2004, respectively). Table 1 reports when and which
kind of clinical specimen is considered suitable for AST in
case of a positive culture.
Comparing results of 1999 versus 2004, disk diffusion
was used in 6 (8.1%) versus 1 (1.2%) laboratory; manual
systems for MIC detection were performed by 58 (78.4%)
versus 82 (95.3%) laboratories. Ten (13.5%) versus 3 (3.6%)
laboratories declared to use both systems. The adopted
commercial methods are reported in Table 2. MICs were
evaluated according to the CLSI M27-A2 document. Eleven
(10.8%) versus 3 (3.6%) laboratories adopted different
diagnostic techniques in association.
Tested drugs are generally representative of the used
commercial kits.
Sixty of seventy-four (81.1%) versus 70/86 (81.4%) of
the laboratories declared to report to clinicians all the tested
drugs (in 1999 and in 2004, respectively), whereas 5 (6.7%)
versus 6 (7.0%) considered the AST results an exclusive
laboratory testing not to be transmitted to clinicians.
However, 9 (12.2%) versus 10 (13.7%) (in 1999 and in
2004, respectively) laboratories confirmed to report to
clinicians only the results of selected drugs such as
amphotericin B, flucytosine, fluconazole, itraconazole,
and ketoconazole.
The recent development of new antimycotic drugs
improved the rates of recovery from systemic mycoses.
ASTs are more frequently requested by clinicians; however,
they still represent a true challenge for microbiologists,
particularly because of the lack of standardization in
interpretative criteria.
In a similar survey performed in 1992 on 94 laboratories
in 73 province capitals, 18.1% of participants performed
AST on all isolates, whereas 54.3% only in some cases
(Farina et al., 1995).Disk diffusion technique was the most commonly used
method (30.9%) in 1992, although occasionally, the
laboratory did not follow standard procedures. This was
especially true for the choice of medium, because very
often, only either Sabouraud dextrose agar or blood agar
was used. Commercial kits were very often used, whereas
automated systems were not so common (7.4%).
Most laboratories (76.1%) reported to clinicians all the
tested antifungal drugs, regardless of their clinical use
(systemic or local), of the isolated fungus, and of the clinical
specimen; 8.5% of laboratories did not report any result, and
the remaining 15.4% only reported some antifungal drugs
(mainly flucytosine) and only in specific cases.
The survey shows that the same percentage (27.5%) of
participants in both 1992 and 1999 declare that they do not
perform AST, whereas this number decreased to 15.7% in
2004. The percentage of laboratories that perform AST on
all isolates (16.7%) or only in some cases (55.9%) were
similar in 1992 and 1999. The analysis of the 2004 survey
shows that the ratio of laboratories performing AST
changed, probably because of a better microbiologist
education. In fact, the percentage of laboratories that never
perform AST had decreased to 12.7%, whereas 71.6% run
AST in some selected cases.
As in the past, in vitro tested drugs are those included
in the commercial panels. Data about the adopted criteria
for reporting of results are very similar (in both 1999 and
2004) to those observed in 1992, showing that sometimes
the microbiologists do not give the clinicians an appropri-
ate answer based on the clinical use of the drug (either
systemic or local), the isolated fungus, and the clinical
specimen type.
If the interpretative criteria were often bhomemadeQ
(criteria suggested by manufacturers rather than the CLSI
recommendations: 45.9% versus 54.1%, in 1992 and 1999,
respectively), the last survey shows that only 5.8% of
laboratories do not follow CLSI (2002) (NCCLS, 2002) or
EUCAST (2003) recommendations.
Even if no fundamental changes occurred in indications
and interpretation of AST from the early 1990s, many
technical improvements have been observed. Compared
with the 1992 survey, more attention was found in 1999 in
the choice of medium, but actually, disk diffusion is only
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used: the 2004 data confirm the 1999 results (95.3% versus
78.4%, respectively), showing the particular trend of the
Italian market. Few laboratories (10/74, 13.5%) used more
than 1 technique.
The situation in Italy is quite similar to the one in the
United States: Sensititre and Etest together dominate the
market (64.5%), and a similar distribution between the 2
techniques is observed in both Countries. In fact, Sensititre
is the most commonly used technique in both Italy (60.7%)
and the United States (59%), followed by Etest (18.7%
versus 15%) (Espinel-Ingroff et al., 1998). ATB Fungus is
only used by 15.2% of the Italian laboratories, and only
1.2% perform disk diffusion methods. On the contrary, in
France, the most frequently used methods are ATB Fungus
and Etest (56% and 41%, respectively), or a combination of
2 or more methods (38%), and 10% of laboratories perform
agar diffusion testing (Blanc et al., 2005).
In conclusion, it seems that Italy largely prefers new
technologies, confirming the interest in the progresses in
the field and the presence of an important commercial
market. However, AST is difficult to be correctly managed,
and it could be performed in particular clinical cases only
in very well-trained centers, even if standardization is now
largely better than in the past (Negroni et al., 2000; Reilly
et al., 1999). Moreover, the low level of criticism in
reporting the results suggests that mycology have to be
taught both as a microbiologic and technical discipline and
as a part of infectious disease programs, to improve
knowledge about indications, method choice, and interpre-
tative criteria for AST both for clinical microbiologists and
clinicians. This concern is confirmed by several nationwidesurveys in Italy (Farina et al., 2000) and in France (Eloy
et al., 2005).References
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